SPOTLIGHT -
Novel Treatment Advances in Differentiated Thyroid Cancer
An overview of therapies in the pipeline for differentiated thyroid cancer and their potential effect on clinical decision-making.
Read More
BRAF Inhibitors and Immunotherapy for Differentiated Thyroid Cancer
The role of BRAF inhibitors and checkpoint inhibitors in differentiated thyroid cancer, and potential considerations for using BRAF inhibition as redifferentiation therapy.
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
Currently Available Treatment Options for Patients With R/R DLBCL
Overview of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
